Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway

Journal of Chemotherapy

Volumn 25, Issue 5, 2013, Pages 298-308

  Fan, Yi ^a   Peng, Aihua ^a   He, Shichao ^a   Shao, Ximing ^a   Nie, Chunlai ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Anti angiogenesis; Endothelial cells; Isogambogenic acid; VEGF; VEGFR2

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; CISPLATIN; FOCAL ADHESION KINASE; ISOGAMBOGENIC ACID; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; EMBRYO; FEMALE; GARCINIA; GARCINIA HANBURYI; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOUR ANGIOGENESIS; WESTERN BLOTTING; WOUND HEALING; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PLANTS, MEDICINAL; PROTO-ONCOGENE PROTEINS C-AKT; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84884750006     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000079     Document Type: Article

References (30)

1. Tan W, Lu J, Huang M, Li YB, Chen MW, Wu GS, et al. Anticancer natural products isolated from chinese medicinal herbs. Chin Med. 2011;6:27.
2. Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 2004;27:1769-74.
3. Li QL, Cheng H, Zhu GQ, Yang L, Zhou A, Wang X, et al. Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting. Biol Pharm Bull. 2010;33:415-20.
4. Xie H, Qin YX, Zhou YL, Tong LJ, Lin LP, Geng MY, et al. GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms. Acta Pharmacol Sin. 2009;30:346-54.
5. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res. 2003;48:231-6.
6. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med. 1971;285:1182-6.
7. D'Amore PA, Thompson RW. Mechanisms of angiogenesis. Annu Rev Physiol. 1987;49:453-64.
8. Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol. 2011;81: 1183-91.
9. Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets. 2011;11:624-53.
10. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008;68:1843-50.
11. Aepfelbacher M, Essler M, Huber E, Sugai M, Weber PC. Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:1623-9.
12. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res. 2011;17:4439-50.
13. Ma L, Chen J, Wang X, Liang X, Luo Y, Zhu W, et al. Structural modification of honokiol, a biphenyl occurring in Magnolia officinalis: the evaluation of honokiol analogues as inhibitors of angiogenesis and for their cytotoxicity and structure-activity relationship. J Med Chem. 2011;54:6469-81.
14. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555-77.
15. Liu MY, Pang XF, Yi TF, Cho SG, Qu W, Pinkaew D, et al. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting Rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res. 2009;69:518-25.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
17. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl). 2003;81:20-31.
18. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem. 2000;275:10661-72.
19. Soga N, Namba N, McAllister S, Cornelius L, Teitelbaum SL, Dowdy SF, et al. Rho family GTPases regulate VEGFstimulated endothelial cell motility. Exp Cell Res. 2001; 269:73-87.
20. Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol. 2008;75:1083-92.
21. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res. 2007;67:6899-906.
22. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5:203-20.
23. Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:33-7.
24. Hong SY, Kwak KW, Ryu CK, Kang SJ, Chung KH. Antiproliferative effects of 6-anilino-5-chloro-1H-benzo[d]imidazole-4,7-dione in vascular smooth muscle cells. Bioorg Med Chem. 2008;16:644-9.
25. Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factoralpha in rat mesangial cells. J Biol Chem. 1998;273:4027-34.
26. Alblas J, Slager-Davidov R, Steenbergh PH, Sussenbach JS, van der Burg B. The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene. 1998; 16:131-9.
27. van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, et al. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/ anti-invasion therapy. Drug Discov Today. 2011;16:219-28.
28. Kozma R, Ahmed S, Best A, Lim L. The Ras-related protein Cdc42hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3t3 fibroblasts. Mol Cell Biol. 1995;15:1942-52.
29. Swart-Mataraza JM, Li ZG, Sacks DB. IQGAP1 is a component of Cdc42 signaling to the cytoskeleton. J Biol Chem. 2002;277:24753-63.
30. Kholmanskikh SS, Koeller HB, Wynshaw-Boris A, Gomez T, Letourneau PC, Ross ME. Calcium-dependent interaction of Lis1 with IQGAP1 and Cdc42 promotes neuronal motility. Nat Neurosci. 2006;9:50-7.